Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

3 Months Ended

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

					Weighted			Weighted Average
	Number of				Average			Remaining
	Options				Exercise Price			Contractual Life
Outstanding, June 30, 2013			1,508,334		$	4.50				4.6
Granted			2,835,000		$	3.14
Outstanding, June 30, 2014			4,343,334		$	3.61				5.6
Granted			360,000		$	1.82
Forfeited			(197,916)		$	3.70
Outstanding, September 30, 2014			4,505,418		$	3.46				5.6

Exercisable at September 30, 2014			1,591,251		$	4.21				4.0

Schedule Of Warrants Issued To Agents Activity [Table Text Block]

AntriaBio issued warrants to agents and note holders in conjunction with the closing of its convertible notes payable as follows:

					Weighted			Weighted Average
	Number of				Average			Remaining
	Warrants				Exercise Price			Contractual Life
Outstanding, June 30, 2013			293,092		$	2.21				4.1
Warrants issued to note holders			225,259		$	1.89
Warrants issued to note holders			4,039,184		$	1.98
Warrants issued to related party			39,117		$	7.50
Warrants issued in private placement			6,287,679		$	2.34
Warrants issued to placement agent			290,861		$	1.56
Warrants issued for investor relations			66,667		$	3.34
Warrants exercised			(100,550)		$	1.17
Warrants forfeited			(41,570)		$	1.17
Outstanding, June 30, 2014			11,099,739		$	2.21				3.6
Outstanding, September 30, 2014			11,099,739		$	2.21				3.3

Stock Option

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

AntriaBio has computed the fair value of all options granted during the three months ended September 30, 2014 using the following assumptions:

Expected volatility		92	%
Risk free interest rate		1.69	%
Expected term (years)		5
Dividend yield		0	%

Black Scholes Pricing Model

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

Significant assumptions were as follows:

Expected volatility		92% - 97%
Risk free interest rate		0.78% - 2.21%
Warrant term (years)		3 - 7
Dividend yield		0	%

Lattice Model

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

The estimated fair value was derived using the lattice model with the following assumptions:

Expected volatility		93	%
Risk free interest rate		2.21	%
Warrant term (years)		7
Dividend yield		0	%